menu
    • menu
    [{"orgOrder":0,"company":"Tharimmune","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Tharimmune","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.01,"dosageForm":"Film","sponsorNew":"Tharimmune \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Tharimmune \/ ThinkEquity"},{"orgOrder":0,"company":"Tharimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TH104","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Tharimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Tharimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tharimmune \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tharimmune

    Menu

    Tharimmune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tharimmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Tharimmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalmefene Hydrochloride

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $11.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Tharimmune, Inc. Announces Closing of $11 Million Public Offering

                            Details : The company intends to use the net proceeds for the advancement of its phase 2 trial evaluating, TH104 (nalmefene) for the treatment of moderate-to-severe cholestatic pruritis in primary biliary cholangitis.

                            Brand Name : TH104

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 30, 2023

                            Lead Product(s) : Nalmefene Hydrochloride

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $11.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tharimmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Tharimmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TH104

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Pri...

                            Details : TH104 is a product which has been developed by embedding drug onto a proprietary transmucosal buccal film which adheres to the inside of the mouth. It isbeing evaluated for the treatment of chronic pruritis in primary biliary cholangitis (PBC).

                            Brand Name : TH104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : TH104

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth